about
Headache therapy with neuronal stabilising drugs.Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis.Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire).Delayed diagnosis in pediatric headache: an outpatient Italian survey.Lifetime and actual prevalence of pain and headache in multiple sclerosis.Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.Response competition and response inhibition during different choice-discrimination tasks: evidence from ERP measured inside MRI scanner.Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis.Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases.A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in ItalyEfficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational studyThyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study
P50
Q37188685-2BE43942-9C3C-44BF-B9A0-A84E9138EB14Q38125249-599F2689-E959-4262-BBEC-D69211A6C2B2Q41386664-AC27E125-580A-4B49-9FFF-D33839D9A8ABQ43073589-7B8D61D4-9667-41D2-B284-0AF6E8C5E3E2Q43857891-39166741-0CE7-41EB-AE79-B928BC8C5554Q44017725-C0EF6AEF-0411-4850-8C92-CBB967EC31A7Q44157548-36BFBC2C-A94D-45E3-BCE3-F76791B88228Q44388462-7A730A18-5A4F-4B54-8053-E823DD656BBCQ45164569-57EA1382-928D-40FD-B0FE-21C1B83AEAF0Q46040058-54F3DB1F-0519-49E1-BC46-33F57A1A5F19Q46382227-0CAE9EED-A4E0-41BF-A813-40DD87E92953Q48177354-2C3ACD4E-43CC-4771-8BFC-2244043B7681Q48192097-12084DB5-B4DE-4293-A042-3FCD6535D92EQ63285843-0A01F6D8-D220-4D4D-90C7-13A63E02693FQ84396538-71ED2437-2C5A-465C-BBFD-9488BCDAAEF2Q87269301-E6024080-4C2A-48C0-A7C8-0FE30C755292
P50
description
researcher ORCID ID = 0000-0003-0279-0707
@en
wetenschapper
@nl
name
Pietro Annovazzi
@ast
Pietro Annovazzi
@en
Pietro Annovazzi
@es
Pietro Annovazzi
@nl
type
label
Pietro Annovazzi
@ast
Pietro Annovazzi
@en
Pietro Annovazzi
@es
Pietro Annovazzi
@nl
prefLabel
Pietro Annovazzi
@ast
Pietro Annovazzi
@en
Pietro Annovazzi
@es
Pietro Annovazzi
@nl
P106
P31
P496
0000-0003-0279-0707